Treatment of Inoperable Metastatic Parathyroid Carcinoma with PTH-Driven Hypercalcemia

Clinical Scenario

This protocol addresses inoperable metastatic parathyroid carcinoma in which persistent PTH excess drives clinically significant hypercalcemia. Surgical resection is no longer feasible, making systemic control of the biochemical consequences the central therapeutic priority.

Key Clinical Challenge

PTH-driven hypercalcemia is the primary source of morbidity and mortality in this population. The main treatment goal is controlling and normalising serum PTH and calcium levels, with ongoing biochemical re-assessment to gauge response.

Treatment Approach

Management centres on calcimimetic therapy — cinacalcet acts by modulating calcium receptors on the parathyroid gland to directly attenuate PTH synthesis and lower serum calcium. The full titration schedule, dosing strategy, and monitoring protocol are detailed in the complete regimen.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1007/s11864-011-0171-3

The primary treatment goal for inoperable metastatic parathyroid carcinoma is controlling PTH-driven hypercalcemia as it is the main cause of morbidity and mortality.
The calcimemetic drugs act by modulating calcium receptors on the parathyroid gland, thereby directly attenuating PTH synthesis and ultimately lowering the serum calcium level.
One multicenter, single-arm, dose-titrating study has shown a durable clinical effect in achieving control of serum PTH and calcium levels in inoperable patients.

View source ↗